Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Share (Tables)

Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2021

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
EPS Numerator:
Net income (loss)	$	(20,952)	$	(14,174)	$	4,727	$	(10,507)
EPS Denominator—Basic:
Weighted-average common shares outstanding		170,886		168,932		170,297		168,658
EPS Denominator—Diluted:
Weighted-average common shares outstanding		170,886		168,932		170,297		168,658
Dilutive effect of stock options, restricted stock units and shares under Purchase Plan		—		—		6,155		—
Weighted-average shares outstanding and common stock equivalents		170,886		168,932		176,452		168,658

Net income (loss) per share
Basic	$	(0.12)	$	(0.08)	$	0.03	$	(0.06)
Diluted	$	(0.12)	$	(0.08)	$	0.03	$	(0.06)

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Outstanding stock options		30,490		27,646		9,450		27,646
Restricted stock units		234		—		4		—
Purchase Plan		313		59		—		59
Total		31,037		27,705		9,454		27,705